Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: J Thromb Thrombolysis

Search In Journal Title:

Abbravation: Journal of Thrombosis and Thrombolysis

Search In Journal Abbravation:

Publisher

Springer US

Search In Publisher:

DOI

10.1002/chin.199108345

Search In DOI:

ISSN

1573-742X

Search In ISSN:
Search In Title Of Papers:

Proceedings of the 10th National Conference on Ant

Authors: David A Garcia
Publish Date: 2009/11/17
Volume: 29, Issue: 2, Pages: 147-147
PDF Link

Abstract

The 10th National Conference on Anticoagulant Therapy sponsored by the Anticoagulation Forum was held in San Diego CA on May 7–9 2009 The Anticoagulation Forum’s conference provided a unique opportunity to network and learn with professional colleagues with expertise in the diagnosis and treatment of thrombotic disorders The 3day conference included an outstanding roster of international expert speakers whose presentations are published in these proceedings As in the past members had an opportunity to present abstracts of original research and case reports Over 50 abstracts were presented and are reprinted in this supplementThe Anticoagulation Forum was founded in 1991 by Dr Jack Ansell in response to the need for a professional group to focus on the discipline of anticoagulation management and related therapies The AC Forum is a multidisciplinary nonprofit organization that works to improve the quality of care for patients taking antithrombotic medications The goals of the AC Forum are to provide education and networking opportunities for health care professionals to promote the clinical application of evidencebased practices to facilitate research aimed at improving health outcomes and to inform healthcare policy regulatory agencies and industry about best practicesThe AC Forum has been an advocate for improved anticoagulation care through the establishment of anticoagulation clinics the hosting of webbased education sessions and the development of clinical guidelines In addition the AC Forum has served the interest of patients taking anticoagulants by promoting increased availability of selfmonitoring and by advocating for appropriate reimbursement from thirdparty payers Many members of the AC Forum are actively engaged in clinical trials testing new and exciting antithrombotic drugs for the treatment of venous and arterial thromboembolism These new drugs may have a major impact on the traditional responsibilities of anticoagulation clinics as highlighted by presentations at this year’s conferenceThe AC Forum has also been an active supporter and partner in the development of a national certification program for providers who manage oral anticoagulation At this year’s meeting approximately 60 individuals sat for the examination delivered by the National Certification Board for Anticoagulation ProvidersThe Anticoagulation Forum wished to express its gratitude to the pharmaceutical and device manufacturers’ industry for their generous support of the meeting ARYx Therapeutics AstraZeneca Boehringer Ingelheim Pharmaceuticals BristolMyers Squibb and Pfizer CSL Behring GlaxoSmithKline Inverness Medical Innovations ITC OrthoMcNeil Janssen Scientifc Affairs Philips Remote Cardiac Services Roche Diagnostics SanofiAventis and Tapestry Medical


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. The inhibition in tumor necrosis factor-α-induced attenuation in endothelial thrombomodulin expression by carvedilol is mediated by nuclear factor-κB and reactive oxygen species
  2. Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction
  3. Does supervised exercise after deep venous thrombosis improve recanalization of occluded vein segments? A randomized study
  4. Anticoagulation in the management of venous thromboembolism in the cancer patient
  5. Association between sleep condition and arterial stiffness in Chinese adult with nonalcoholic fatty liver disease
  6. In vitro shear stress modulates antithrombogenic potentials of human endothelial progenitor cells
  7. Polymorphism in the methylenetetrahydrofolate reductase (C677T) gene and homocysteine levels: a comparison in Brazilian patients with coronary arterial disease, ischemic stroke and peripheral arterial obstructive disease
  8. Role of thrombophilia testing: con
  9. Venous thromboembolism and cancer: a systematic review
  10. Dabigatran-associated subdural hemorrhage: using thromboelastography (TEG ® ) to guide decision-making
  11. Comparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey ventricular assist device
  12. The relationship between gender and age with monocyte tissue factor expression
  13. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability
  14. A comparison of direct thrombin inhibitors in the treatment of heparin-induced thrombocytopenia: a single institution experience
  15. US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins
  16. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study
  17. Abnormal asymmetric dimethylarginine/nitric oxide balance in patients with documented coronary artery disease: relation to renal function and homocysteine
  18. Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention
  19. Cardiovascular risk factors and outcome in patients with retinal vein occlusion
  20. Impact of type of thrombolytic agent on in-hospital outcomes in ST-segment elevation myocardial infarction patients in the Middle East
  21. Prognostic significance of multidetector computed tomography in normotensive patients with pulmonary embolism: rationale, methodology and reproducibility for the PROTECT study
  22. Increased platelet activation in patients with slow coronary flow
  23. Biomarkers of deep venous thrombosis
  24. Thromboembolic complications following a first isolated episode of superficial vein thrombosis: a cross-sectional retrospective study
  25. The impact of factor Xa inhibition on axial dependent arterial thrombus formation triggered by a tissue factor rich surface
  26. New oral Xa and IIa inhibitors: updates on clinical trial results
  27. Spontaneous coronary thrombosis following thrombolytic therapy for acute cardiovascular accident and stroke: a case study
  28. Anti-coagulant activity of a metalloprotease: further characterization from the Indian cobra ( Naja naja ) venom
  29. Evaluation of the Alere D-dimer test for point of care testing
  30. Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight heparin in patients with mechanical heart valves
  31. Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial
  32. Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism
  33. Methylenetetrahydrofolate reductase (MTHFR) C677T genetic polymorphism and late infarct-related coronary artery patency after thrombolysis
  34. Are surgical patients at risk of venous thromboembolism currently meeting the Surgical Care Improvement Project performance measure for appropriate and timely prophylaxis?
  35. Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait

Search Result: